Digestive system neoplasm
Therapeutic area
Oncology
Rare disease
No
- Definition
- A neoplasm (disease) that involves the digestive system.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Digestive system neoplasm
- Therapeutic area
- Oncology
- digestive system neoplasm
- GI neoplasm
- GI system neoplasm
- GI system tumor
- GI system tumour
- GI tumor
- GI tumour
- digestive neoplasm
- digestive system neoplasm (disease)
- digestive system tumor
- digestive system tumour
- digestive tumor
- digestive tumour
- gastrointestinal neoplasm
- gastrointestinal system neoplasm
- gastrointestinal system tumor
- gastrointestinal system tumour
- gastrointestinal tumor
- gastrointestinal tumour
- neoplasm of GI system
- neoplasm of digestive system
- neoplasm of gastrointestinal system
- neoplasm of the GI system
- neoplasm of the digestive system
- neoplasm of the gastrointestinal system
And 12 more, listed on the interactive page.
- All therapeutic areas
- Oncology
- Severity
- Severe
- MONDO ID
- MONDO:0021223
- Parent condition
- MONDO:0005070
Related records
Broader conditions (6)
- Cancer or benign tumor
- Disease
- Disease by etiologic mechanism
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
Narrower conditions (736)
- Adenocarcinoma of gallbladder and extrahepatic biliary tract
- Adenoid ameloblastoma
- Adenoid cystic carcinoma of oropharynx
- Adenoma of pancreas
- Adenoma of small intestine
- Adenomatoid odontogenic tumor
- Adenomatous colon polyp
- Adenosquamous bile duct carcinoma
- Adenosquamous colon carcinoma
- Adult hepatocellular carcinoma
- Aflatoxin-related hepatocellular carcinoma
- Ameloblastic carcinoma
- Ameloblastoma
- Ampulla of vater adenocarcinoma
- Ampulla of vater adenosquamous carcinoma
- Ampulla of vater cancer
- Ampulla of vater clear cell adenocarcinoma
- Ampulla of vater mucinous adenocarcinoma
- Ampulla of vater neoplasm
- Ampulla of vater small cell neuroendocrine carcinoma
Trials (836)
- 'Penny', a SMS Text-based Chatbot Intervention for Medication Adherence and Side Effect Management Among Patients With GI Cancers
- 131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients
- 2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers
- 5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer
- 68Ga-PMD22 PET/CT Examination Targeting CLDN18.2
- 89Zr-AMG211 PET Imaging Study
- 89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients
- A Clinical Safety and Efficacy Study of Mebendazole on GI Cancer or Cancer of Unknown Origin.
- A Clinical Study of Arfolitixorin in Patients With mCRC
- A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
- A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors
- A Clinical Study on the Safety and Efficacy of CAR-T Therapy for the TM4SF1-positive Tumors of Digestive System
- A Clinicobiological Database in Metastatic Digestive Cancers
- A Comparative Study of CCI, EmSFI, and FTRST Scoring Systems
- A Disposable Endoscopic Closing Device Used for the Closure of Gastrointestinal Tissue
- A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients
- A Feasibility Trial of Geriatric Assessment and Management for Older Cancer Patients
- A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
- A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
- A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
Drugs in development (13)
- Alectinib Phase 2
- Cisplatin Phase 1
- Flucytosine Phase 1
- Fluorouracil Phase 2
- Irinotecan hydrochloride Phase 1
- Leucovorin calcium Phase 2
- Pasireotide Phase 1
- Picoplatin Phase 1
- Propranolol Phase 2
- Pyrotinib Phase 2
- Tislelizumab Phase 1
- Trastuzumab Phase 2
- Trastuzumab deruxtecan Phase 2
Other linked drugs (1)
- Sunitinib malate